SF3B1 and acute lymphoblastic leukemia: Driven by the sensitivity of T-ALL cells to SF3B1 inhibitors despite the general absence of SF3B1 mutations (26), we sought out to further investigate alterations in the levels and genetic status of SF3B1 in T-ALL.